Search clinical trials for: PDS290

Total 10 results

Novo Nordisk A/S

Completed

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers Obesity

Netherlands
Novo Nordisk A/S

Terminated

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
University of Colorado, Denver
Novo Nordisk A/S

Recruiting

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) (SIB)

Type 2 Diabetes | Chronic Inflammation | Intestinal Permeability

United States
Novo Nordisk A/S

Completed

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers Obesity

Netherlands
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 (PATH-2)

Secondary Hyperparathyroidism | End Stage Kidney Disease

United States, Bulgaria, Portugal, Spain, Serbia, Poland
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 (PATH-1)

Secondary Hyperparathyroidism | End-stage Kidney Disease (ESKD)

United States, Bulgaria, Spain, Portugal, Poland, Serbia
Novo Nordisk A/S

Completed

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

Diabetes Mellitus, Type 2

Germany
GlaxoSmithKline

Completed

A Long Term Prospective Follow Up Study For The CATO Study (SAS30018/SER9702)

Asthma

Netherlands

3

Subscribe